

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/535,042
Filing Date	05/13/2005
First Named Inventor	Downes et al.
Group Art Unit	1646 1656
Examiner Name	Unknown Alexander Kim
Attorney Docket Number	SALK3140US-1 (088802-9803)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	6184353		Evans	02-06-2001	

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ⁶
	A2	Blumberg and Evans (1998). Orphan nuclear receptors--new ligands and new possibilities. Genes Dev. 12(20), 3149-55.	
	A3	Blumberg et al. (1998). SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12(20), 3195-3205.	
	A3	Chiang (2002) Bile Acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev. 23(4), 443-463.	

Examiner Signature	/Alexander Kim/	Date Considered	07/18/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. *See attached Kinds of U.S. Patent Documents. †Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ‡For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. †Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. †Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number	10/535,042
Filing Date	05/13/2005
First Named Inventor	Downes et al.
Group Art Unit	4646 1656
Examiner Name	Unknown Alexander Kim
Attorney Docket Number	SALK3140US-1 (088802-9803)

(use as many sheets as necessary)

Sheet	2	of	5
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	P ²
	A4	Egea et al. (2000). Crystal structure of the human RXRa ligand-binding domain to its natural ligand: 9-cis retinoic acid EMBO J. 19, 2592-2601.	
	A5	Evans RM. (1988) The steroid and thyroid hormone receptor superfamily. Science. 240(4854), 889-895.	
	A6	Forman et al. (1995). Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687-693.	
	A7	Goodwin et al (2000). A regulatory cascade of the nuclear receptors FXR, SHP-1, and LXR-1 represses bile acid biosynthesis. Mol Cell. 6(3), 517-526.	
	A8	Grober et al., (1999) Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. J Biol Chem. 274(42), 29749-54	
	A9	Jez et al. (2000) Dissection of malonyl-coenzyme A decarboxylation from polyketide formation in the reaction mechanism of a plant polyketide synthase. Biochemistry 39, 890-902.	
	A10	Kast et al. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 277(4), 2908-15.	
	A11	Laffitte et al. (2000). Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem. 275(14), 10638-47	

Examiner
Signature

/Alexander Kim/

Date

Considered

07/18/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/535,042
Filing Date	05/13/2005
First Named Inventor	Downes et al.
Group Art Unit	1646 1656
Examiner Name	Unknown Alexander Kim
Attorney Docket Number	SALK3140US-1 (088802-9803)

(use as many sheets as necessary)

Sheet 3 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ²
	A12	Lattman, Use of the rotation and translation functions. <i>Meth. Enzymol.</i> 115:55-77 (1985)	
	A13	Makishima et al, (1999) Identification of a nuclear receptor for bile acids. <i>Science</i> . 284(5418), 1362-5	
	A14	McPherson, Crystallization of proteins from polyethylene glycol. <i>J. Biol. Chem.</i> 251:6300-6303 (1976)	
	A15	Nicolaou et al. (2000). Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. <i>J. Am. Chem. Soc.</i> 122, 9939 – 9953 (2000)	
	A16	Nicolaou et al. (2000). Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10 000-membered benzopyran library by directed split-and-pool chemistry using nanoKans and optical encoding. <i>J. Am. Chem. Soc.</i> 122, 9954 – 9967 (2000)	
	A17	Nicolaou et al. (2000). Natural product-like combinatorial libraries based on privileged structures. 3. The "Libraries from Libraries" principle for diversity enhancement of benzopyran libraries. <i>J. Am. Chem. Soc.</i> 122, 9968 – 9976 (2000)	
	A18	Parks et al. (1999). Bile acids: natural ligands for an orphan nuclear receptor. <i>Science</i> . 284(5418). 1365-8	

Examiner
Signature

/Alexander Kim/

Date
Considered

07/18/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/535,042
			Filing Date	05/13/2005
			First Named Inventor	Downes et al.
			Group Art Unit	4646 1656
			Examiner Name	Unknown Alexander Kim
(use as many sheets as necessary)			Attorney Docket Number	SALK3140US-1 (088802-9803)
Sheet	4	of	5	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	†*
	A19	Pellicciari et al. (2002). 6-alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 45(17), 3569-72	
	A20	Rochel et al. (2000). The Crystal Structure of the Nuclear Receptor for Vitamin D Bound to its Natural Ligand. Mol Cell 5, 173-179	
	A21	Sinal et al. (2000). Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell: 102(6), 731-44	
	A22	Stehlin et al. (2001). X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation. EMBO J. 20(21), 5822-31	
	A23	Urizar et al (2000). The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem. 275(50), 39313-7	
	A24	Urizar et al. (2002). A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 296(5573), 1703-6	
	A25	Wang et al. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 3(5), 543-53	

Examiner Signature	/Alexander Kim/	Date Considered	07/18/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/535,042
			Filing Date	05/13/2005
			First Named Inventor	Downes et al.
			Group Art Unit	1646 1656
			Examiner Name	Unknown Alexander Kim
(use as many sheets as necessary)			Attorney Docket Number	SALK3140US-1 (088802-9803)
Sheet	5	of	5	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A26	Watkins et al. (2001). The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity, Science, 292, 2329-2333	
	A27	Xu et al. (2001). Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 98(24), 13919-24	

Examiner Signature	/Alexander Kim/	Date Considered	07/18/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.